The presence of minimal residual disease evidenced by NPM1-mutated transcripts provides powerful prognostic information in patients with standard-risk acute myeloid leukaemia, potentially changing current approaches to risk stratification and treatment selection. A report in the New England Journal of Medicine described AML patients included in the National Cancer Institute AML17 trial of intensive therapy who ...
Minimal residual disease prognostic in standard-risk AML
By Tony James
21 Jan 2016